000 03357nam a22005535i 4500
001 978-3-031-75806-5
003 DE-He213
005 20250516160158.0
007 cr nn 008mamaa
008 241121s2024 sz | s |||| 0|eng d
020 _a9783031758065
_9978-3-031-75806-5
050 4 _aRM300-666
072 7 _aMMG
_2bicssc
072 7 _aMED071000
_2bisacsh
072 7 _aMKG
_2thema
082 0 4 _a615
_223
245 1 0 _aPublic-Private-Partnerships in Drug Research and Development
_h[electronic resource] /
_cedited by Martin C. Michel, Heike A. Wieland.
250 _a1st ed. 2024.
264 1 _aCham :
_bSpringer Nature Switzerland :
_bImprint: Springer,
_c2024.
300 _aXI, 196 p. 100 illus., 30 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aHandbook of Experimental Pharmacology,
_x1865-0325 ;
_v286
505 0 _aNovel and proven models of Public Private and Public Private Partnerships in Healthcare An Update -- Project based Public private collaborations -- Collaborative Innovations in Childhood Cancer Therapies -- Reaching outer space and enabling the mRNA revolution a critical role of partnerships for successful drug and vaccine development -- The Alliance between the German Cancer Research Center and Bayer a retrospective of an innovative collaboration model -- Life Science Incubation at LabCentral BioLabs with Partners Extending from the US to Europe -- Innovation at the Interface between Academia and Industry The BioMed X Model -- From innovator result driven to multi actor impact oriented Public Private Partnerships Integrating the patient perspective -- The Legal Framework for PPP in Drug R&D.
520 _aCollaborative approaches are becoming a key driver in drug discovery and development. They come in many types and forms ranging from project-based collaborations and strategic alliances to large international consortia. The volume discusses various types of such collaboration including the specific uses, advantages, and challenges. Based on the nature of public-private partnerships, we present views and experiences from academia, industry, and public stakeholders.
541 _fUABC ;
_cPerpetuidad
650 0 _aPharmacology.
650 0 _aMedicine
_xResearch.
650 0 _aBiology
_xResearch.
650 1 4 _aPharmacology.
650 2 4 _aBiomedical Research.
700 1 _aMichel, Martin C.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aWieland, Heike A.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031758058
776 0 8 _iPrinted edition:
_z9783031758072
776 0 8 _iPrinted edition:
_z9783031758089
830 0 _aHandbook of Experimental Pharmacology,
_x1865-0325 ;
_v286
856 4 0 _zLibro electrónico
_uhttp://libcon.rec.uabc.mx:2048/login?url=https://doi.org/10.1007/978-3-031-75806-5
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c276856
_d276855